Study of Effectiveness and Safety of Piascledine in the Treatment of Patients with Osteoarthritis of the Knee

O.I. Ivashkivskyi, T.A. Karasevska, M.B. Dzhus, R.A. Potiomka, M.S. Kulyk

Abstract


The article presents the literature data and the results of own investigation of effectiveness and safety of Piascledine. The study included 20 women (average age 58.90 ± 7.36 years old, height 164.60 ± 5.26 cm, weight 80.40 ± 12.94 kg, BMI 29.8 ± 1.4). The study design included observation of the participants and interview before the treatment and in 1, 3 and 5 months after the course with Piascledine. The patients received Piascledine 1 capsule 300 mg once a day during 5 months. There were registered significant decrease in pain syndrome both in rest (62.60 ± 14.06 vs 43.70 ±19.23; p < 0.05) and on move (77.70 ± 11.65 vs 58.50 ± 14.84; p < 0.05), in duration of morning stiffness (19.5 ±11.57 vs 14.30 ± 5.85; p < 0.05) and its intensity (59.1 ± 21.8 vs 45.40 ± 21.12; p < 0.05), as well reduction of total index of WOMAC in 3 months (1259.7 ± 316.7 vs 1028.7 ± 381.7; р < 0.05) and in 5 months (1031.4 ± 336.9; р < 0.05) of treatment with Piascledine. There were determined reduction of a total demand for non-steroid anti-inflammatory drugs, high compliance in patients, effectiveness and safety of Piascledine during the treatment of osteoarthritis of the knee that reduces pain syndrome intensity and improves functional activity in patients.


References


Бадокин В.В. Пиаскледин — хондропротективный препарат с антицитокиновой активностью // Consilium Medicum. — 2007. — Т. 9, № 8. — С. 147-152.

Борткевич О.П. Ефективність препарату Піаскледин® 300 у лікуванні пацієнтів з остеоартрозом: доведено в дослідженнях, підтверджено європейською практикою // Український ревматологічний журнал. — 2015. — № 1 (59). — С. 61-65.

Манойленко Т.С., Дорогой А.П., Гандзюк В.А., Мороз Д.М., Ревенко І.Л. Хвороби системи кровообігу як медико-соціальна і суспільно-політична проблема: Аналітико-статистичний посібник / За ред. В.М. Коваленко, В.М. Корнацького. — К., 2014. — 279 с.

Appelboom T., Schuermans J., Verbruggen G. et al. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study // Scand. J. Rheumatol. — 2001. — 30 (4). — Р. 242-47.

Berenbaum F. Targeted therapies in osteoarthritis: a systematic review of the trials on http://www.clinicaltrials.gov // Best Pract. Res Clin. Rheumatol. — 2010. — 24. — Р. 107-19.

Blotman F., Maheu E., Wulwic A. et al. Efficacy and safety of avocado/soybean unsaponifiables in the treatment osteoarthritis of the knee and hip // Rev. Rhum. (Engl. Ed.). — 1997. — 64. — Р. 825-34.

Christenen R., Barteles E.M., Astrup A. et al. Symptomatic efficacy of avocado/soybean unsaponifiables (ASU) in Osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials // Osteoarthritis Cartilage. — 2008. — 16 (2). — Р. 339-408.

Ernst E. Avocado/soybean unsaponifiables (ASU) for osteoarthritis — a systematic review // Clin. Rheumatol. — 2003. — 22. — Р. 285-88.

Henrotin Y., Deberg M., Crielaard J. et al. Avocado/soybean unsaponifiables prevent the inhibitory effect of osteoarthritic subchondral osteoblasts on aggrecan and type II collagen synthesis by chondrocytes // J. Rheumatol. — 2006. — 33 (8). — Р. 1668-78.

Henrotin Y., Sanchez C., Deberg M. et al. Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes // J. Rheumatol. — 2003. — 30 (8). — Р. 1825-34.

Maheu E., Mazieres B., Valat J.-P. et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip // Arthritis Rheum. — 1998. — 41. — Р. 81-91.

Maheu E., Cadet C., Marty M. et al. Evaluation of the Structure-Modifying Effect of avocado/soybean unsaponifiables (ASU) in Hip Osteoarthritis (OA): Results of the American College of Rheumatology, Pennsylvania, PA. — 2009, abstr. 847.

Lequesne M., Maheu E., Cadet C. et al. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoartritis of the hip // Arthritis Rheum. Arthritis Rheum. — 2002. — 47. — Р. 50-8.

Pavelka K., Coste P., Géher P., Krejci G. Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee // Clin. Rheumatol. — 2010. — Vol. 29, № 6. — P. 659-670.




DOI: https://doi.org/10.22141/1608-1706.5.16.2015.79782

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 TRAUMA

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru